Karuppaiyah Selvendiran

Dr. Karuppaiyah Selvendiran

Dept Obstet & Gynecol, Div Gynecol Oncol, Ctr Comprehens Canc, Ohio State Univ, Columbus, OH 43210, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
RWRoss Wanner
Ross Wanner
JWJohn J. Wallbillich
John J. Wallbillich
USUksha Saini
Uksha Saini
RZRoman Zingarelli
Roman Zingarelli
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran

13 June 2016 in Oncogene
Verified
Journal Article
Closed access
PDF file
USU Saini
U Saini
SNS Naidu
S Naidu
AEA C ElNaggar
A C ElNaggar
HBH K Bid
H K Bid
JWJ J Wallbillich
J J Wallbillich
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran

15 April 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KRKellie S. Rath
Kellie S. Rath
SNShan K. Naidu
Shan K. Naidu
PLPushpa Lata
Pushpa Lata
HBHemant K. Bid
Hemant K. Bid
BRBrian K. Rivera
Brian K. Rivera
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
STAT3 is well corroborated preclinically as a cancer therapeutic target, but tractable translational strategies for its blockade by small molecule inhibitors have remained elusive. In this study, we report the development of a novel class of bifunctional STAT3 inhibitors, based on conjugation of a diarylidenyl-piperidone (DAP) backbone to an N-hydroxypyrroline (–NOH) group, which exhibits minimal toxicity against normal cells and good oral bioavailability. Molecular modeling studies of this class suggested direct interaction with the STAT3 DNA binding domain. In particular, the DAP compound HO-3867 selectively inhibited STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs. HO-3867 exhibited minimal toxicity toward noncancerous cells and tissues but induced apoptosis in ovarian cancer cells. Pharmacologic analysis revealed greater bioabsorption and bioavailability of the active (cytotoxic) metabolites in cancer cells compared with normal cells. The selective cytotoxicity of HO-3867 seemed to be multifaceted, eliciting differential activation of the Akt pathway in normal versus cancer cells. RNAi attenuation experiments confirmed the requirement of STAT3 for HO-3867–mediated apoptosis in ovarian cancer cells. In vivo testing showed that HO-3867 could block xenograft tumor growth without toxic side effects. Furthermore, in primary human ovarian cancer cells isolated from patient ascites, HO-3867 inhibited cell migration/invasion and survival. Our results offer preclinical proof-of-concept for HO-3867 as a selective STAT3 inhibitor to treat ovarian cancer and other solid tumors where STAT3 is widely upregulated. Cancer Res; 74(8); 2316–27. ©2014 AACR.

1 July 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
JWJohn J. Wallbillich
John J. Wallbillich
DCDavid E. Cohn
David E. Cohn
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran

26 February 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAnna Bratasz
Anna Bratasz
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
TWTomasz Wasowicz
Tomasz Wasowicz
ABAndrey Bobko
Andrey Bobko
VKValery V Khramtsov
Valery V Khramtsov
PKPeriannan Kuppusamy
Periannan Kuppusamy
Background: Ovarian carcinoma is the leading cause of mortality among gynecological cancers in the world. The high mortality rate is associated with lack of early diagnosis and development of drug resistance. The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied. Methods: NCX-4040, alone or in combination with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied in cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP) cell lines as well as xenograft tumors grown in nude mice. Electron paramagnetic resonance (EPR) was used for measurements of nitric oxide and redox state. Immunoblotting analysis of A2780 cDDP tumor xenografts from mice was used for mechanistic studies. Results: Cells treated with NCX-4040 (25 μM) showed a significant reduction of cell viability (A2780 WT, 34.9 ± 8.7%; A2780 cDDP, 41.7 ± 7.6%; p < 0.05). Further, NCX-4040 significantly enhanced the sensitivity of A2780 cDDP cells (cisplatin alone, 80.6 ± 11.8% versus NCX-4040+cisplatin, 26.4 ± 7.6%; p < 0.01) and xenograft tumors (cisplatin alone, 74.0 ± 4.4% versus NCX-4040+cisplatin, 56.4 ± 7.8%; p < 0.05), to cisplatin treatment. EPR imaging of tissue redox and thiol measurements showed a 5.5-fold reduction (p < 0.01) of glutathione in NCX-4040-treated A2780 cDDP tumors when compared to untreated controls. Immunoblotting analysis of A2780 cDDP tumor xenografts from mice treated with NCX-4040 and cisplatin revealed significant downregulation of pEGFR (Tyr845 and Tyr992) and pSTAT3 (Tyr705 and Ser727) expression. Conclusion: The results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer cells to cisplatin possibly by depletion of cellular thiols. Thus NCX-4040 appears to be a potential therapeutic agent for the treatment of human ovarian carcinoma and cisplatin-resistant malignancies.

23 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JWJohn J Wallbillich
John J Wallbillich
SJSrirama Josyula
Srirama Josyula
USUksha Saini
Uksha Saini
RZRoman A Zingarelli
Roman A Zingarelli
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
STAT3 is over-expressed in endometrial cancer, and diabetes is a risk factor for the development of type 1 endometrial cancer. We therefore investigated whether glucose concentrations influence STAT3 expression in type 1 endometrial cancer, and whether such STAT3 expression might be inhibited by metformin. In Ishikawa (grade 1) endometrial cancer cells subjected to media with low, normal, or high concentrations of glucose, expression of STAT3 and its target proteins was evaluated by real-time quantitative PCR (qPCR). Ishikawa cells were treated with metformin and assessed with cell proliferation, survival, migration, and ubiquitin assays, as well as Western blot and qPCR. Expression of apoptosis proteins was evaluated with Western blot in Ishikawa cells transfected with a STAT3 overexpression plasmid and treated with metformin. A xenograft tumor model was used for studying the in vivo efficacy of metformin. Expression of STAT3 and its target proteins was increased in Ishikawa cells cultured in high glucose media. In vitro, metformin inhibited cell proliferation, survival and migration but induced apoptosis. Metformin reduced expression levels of pSTAT3 ser727, total STAT3, and its associated cell survival and anti-apoptotic proteins. Additionally, metformin treatment was associated with increased degradation of pSTAT3 ser727. No change in apoptotic protein expression was noticed with STAT3 overexpression in Ishikawa cells. In vivo, metformin treatment led to a decrease in tumor weight as well as reductions of STAT3, pSTAT3 ser727, its target proteins. These results suggest that STAT3 expression in type 1 endometrial cancer is stimulated by a high glucose environment and inhibited by metformin.